{"id":"pegylated-interferon-and-ribavirin","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"10-30","effect":"Hemolytic anemia"},{"rate":"5-15","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Depression and neuropsychiatric effects"},{"rate":"5-10","effect":"Thyroid dysfunction"},{"rate":"5-15","effect":"Neutropenia"},{"rate":"20-40","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2108506","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pegylated interferon alpha binds to interferon-alpha receptors on immune cells, triggering antiviral and immunomodulatory pathways that enhance natural killer cell and T-cell activity. Ribavirin is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase and depletes guanosine pools, reducing hepatitis C virus replication. Together, they work synergistically to clear chronic viral infection.","oneSentence":"Pegylated interferon alpha activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis and replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:23:15.744Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotype-dependent)"}]},"trialDetails":[{"nctId":"NCT02583685","phase":"PHASE2","title":"Switching Regimen in Treating Cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-05-15","conditions":"Chronic Hepatitis C Infection","enrollment":138},{"nctId":"NCT02259855","phase":"PHASE1","title":"Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-01-01","conditions":"Hepatic Insufficiency","enrollment":36},{"nctId":"NCT01340573","phase":"","title":"Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-03-23","conditions":"Chronic Hepatitis C","enrollment":3},{"nctId":"NCT01440595","phase":"PHASE2","title":"Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-28","conditions":"Hepatitis C, Chronic","enrollment":5},{"nctId":"NCT01120795","phase":"PHASE4","title":"Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy","status":"COMPLETED","sponsor":"Melbourne Health","startDate":"2004-02","conditions":"Chronic Hepatitis C","enrollment":55},{"nctId":"NCT00882193","phase":"EARLY_PHASE1","title":"Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2009-05-01","conditions":"Chronic Hepatitis C, Genotype 1, Relapse","enrollment":2},{"nctId":"NCT01180790","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2010-09","conditions":"Hepatitis C","enrollment":122},{"nctId":"NCT02992457","phase":"PHASE4","title":"Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection","status":"COMPLETED","sponsor":"Tanta University","startDate":"2015-01","conditions":"Hepatitis C","enrollment":10000},{"nctId":"NCT01866930","phase":"PHASE3","title":"Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2013-07-11","conditions":"Chronic Hepatitis C Infection","enrollment":453},{"nctId":"NCT03067129","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-20","conditions":"Hepatitis C Virus (HCV)","enrollment":129},{"nctId":"NCT02087111","phase":"PHASE4","title":"Telaprevir in Genotype 3 HCV","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2014-04","conditions":"Hepatitis C","enrollment":14},{"nctId":"NCT03483987","phase":"NA","title":"Re-treatment of HCV Following DAA Failure","status":"TERMINATED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2018-02-10","conditions":"Chronic Hepatitis C","enrollment":18},{"nctId":"NCT00078403","phase":"PHASE2","title":"Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-07","conditions":"HIV Infections, Hepatitis C, Liver Disease","enrollment":333},{"nctId":"NCT00991289","phase":"PHASE2","title":"Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-01","conditions":"HIV Infection, Hepatitis C Infection","enrollment":68},{"nctId":"NCT01482767","phase":"PHASE3","title":"Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-04","conditions":"HIV Infections, Hepatitis C","enrollment":262},{"nctId":"NCT00051077","phase":"PHASE2","title":"Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis B, Hepatitis C","enrollment":""},{"nctId":"NCT00015652","phase":"NA","title":"Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis C","enrollment":24},{"nctId":"NCT00100581","phase":"NA","title":"Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis C","enrollment":2},{"nctId":"NCT01587586","phase":"PHASE2","title":"Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Virus Genotype 1 Infection","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2011-10-18","conditions":"Hepatitis C, Chronic","enrollment":107},{"nctId":"NCT01185028","phase":"PHASE1, PHASE2","title":"A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2010-08","conditions":"Hepatitis C Infection, HIV Infection","enrollment":8},{"nctId":"NCT00381953","phase":"PHASE3","title":"High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2003-02","conditions":"Hepatitis C","enrollment":33},{"nctId":"NCT02247401","phase":"PHASE3","title":"Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-11-04","conditions":"HCV, Hepatitis C Infection, Genotype 4","enrollment":160},{"nctId":"NCT02966795","phase":"PHASE3","title":"A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-01-25","conditions":"Hepatitis C Virus (HCV)","enrollment":84},{"nctId":"NCT01685203","phase":"PHASE2","title":"A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-08","conditions":"Hepatitis C, Chronic","enrollment":316},{"nctId":"NCT02541409","phase":"PHASE2","title":"Directly Observed Therapy for HCV in Chennai, India","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2015-09","conditions":"Hepatitis C, Chronic","enrollment":50},{"nctId":"NCT01425203","phase":"PHASE3","title":"The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-23","conditions":"Chronic Hepatitis C Genotype 1","enrollment":238},{"nctId":"NCT00943761","phase":"PHASE2","title":"A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-10-23","conditions":"Hepatitis C, Chronic","enrollment":45},{"nctId":"NCT02105701","phase":"PHASE3","title":"Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-06-05","conditions":"Hepatitis C Infection","enrollment":420},{"nctId":"NCT01710501","phase":"PHASE2","title":"A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-07","conditions":"Chronic Hepatitis C (CHC)","enrollment":87},{"nctId":"NCT01821963","phase":"PHASE3","title":"Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-04","conditions":"Infection","enrollment":1},{"nctId":"NCT00237484","phase":"PHASE3","title":"Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07-18","conditions":"Hepatitis C, Chronic","enrollment":89},{"nctId":"NCT01741545","phase":"PHASE3","title":"Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-03-31","conditions":"Hepatitis C Virus","enrollment":71},{"nctId":"NCT00845676","phase":"PHASE4","title":"Treatment of Acute Hepatitis C Virus in HIV Co-Infection","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-03","conditions":"Hepatitis C, Human Immunodeficiency Virus, HIV Infections","enrollment":21},{"nctId":"NCT04382339","phase":"PHASE1, PHASE2","title":"Sofosbuvir/Pegylated-interferon Plus Ribavirin With HCV Genotype 4","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2015-03","conditions":"Hepatitis C Virus Infection","enrollment":99},{"nctId":"NCT00086541","phase":"PHASE3","title":"Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2004-06","conditions":"Chronic Hepatitis C","enrollment":515},{"nctId":"NCT01364090","phase":"PHASE4","title":"A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Hepatitis C, Chronic","enrollment":93},{"nctId":"NCT00230854","phase":"PHASE1","title":"Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2005-08","conditions":"Chronic Hepatitis C, Hepatitis, Viral, Human","enrollment":28},{"nctId":"NCT02247440","phase":"PHASE4","title":"HCV-HIV Co-infected Patient Cohort in Thailand","status":"COMPLETED","sponsor":"Institut de Recherche pour le Developpement","startDate":"2014-08","conditions":"Hepatitis C Infection, HIV","enrollment":18},{"nctId":"NCT03069365","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-28","conditions":"Hepatitis C Virus (HCV)","enrollment":101},{"nctId":"NCT00728936","phase":"PHASE1","title":"Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients","status":"COMPLETED","sponsor":"Idera Pharmaceuticals, Inc.","startDate":"2007-09","conditions":"Hepatitis C","enrollment":58},{"nctId":"NCT03833362","phase":"PHASE3","title":"Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2014-05-07","conditions":"Hepatitis C","enrollment":420},{"nctId":"NCT01987453","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-07","conditions":"HCV Infection","enrollment":100},{"nctId":"NCT02202980","phase":"PHASE2","title":"Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-08-04","conditions":"Chronic Hepatitis C","enrollment":273},{"nctId":"NCT01826981","phase":"PHASE2","title":"Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-04","conditions":"Chronic Hepatitis C","enrollment":359},{"nctId":"NCT01726517","phase":"PHASE2","title":"Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-10","conditions":"Chronic Hepatitis C Virus","enrollment":100},{"nctId":"NCT01606800","phase":"PHASE4","title":"Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-01","conditions":"Hepatitis C, Chronic","enrollment":45},{"nctId":"NCT00100659","phase":"PHASE3","title":"PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2004-12","conditions":"Chronic Hepatitis C","enrollment":114},{"nctId":"NCT01370642","phase":"PHASE3","title":"Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-06-27","conditions":"Hepatitis C, Chronic","enrollment":294},{"nctId":"NCT00880763","phase":"PHASE2","title":"A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-20","conditions":"Hepatitis C","enrollment":90},{"nctId":"NCT00704184","phase":"PHASE2","title":"Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-07-25","conditions":"Hepatitis C","enrollment":95},{"nctId":"NCT00704405","phase":"PHASE2","title":"Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-03-27","conditions":"Hepatitis C, Chronic","enrollment":285},{"nctId":"NCT02358044","phase":"PHASE3","title":"Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-02-27","conditions":"Hepatitis C","enrollment":257},{"nctId":"NCT01390844","phase":"PHASE3","title":"Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-21","conditions":"Hepatitis C, Chronic","enrollment":282},{"nctId":"NCT00793793","phase":"PHASE1","title":"Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-09","conditions":"Hepatitis C, Chronic","enrollment":96},{"nctId":"NCT00136214","phase":"","title":"Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2004-03","conditions":"Hepatitis C","enrollment":22},{"nctId":"NCT01314261","phase":"PHASE2","title":"Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-03","conditions":"Chronic Hepatitis C, Hepatitis C Virus (HCV) Infection","enrollment":37},{"nctId":"NCT00851890","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-03","conditions":"Chronic Hepatitis C Virus Infection","enrollment":30},{"nctId":"NCT01609933","phase":"PHASE2","title":"A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-12-18","conditions":"Chronic Hepatitis C","enrollment":32},{"nctId":"NCT01854528","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-06","conditions":"Chronic Hepatitis C Infection","enrollment":148},{"nctId":"NCT01854697","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-03","conditions":"Chronic Hepatitis C Infection","enrollment":311},{"nctId":"NCT02758509","phase":"","title":"Impact of Antiviral Therapy on Gastroesophageal Varices.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2010-01-01","conditions":"Chronic Hepatitis C, Cirrhosis","enrollment":237},{"nctId":"NCT01355289","phase":"PHASE2","title":"Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2011-11","conditions":"Thrombocytopenia","enrollment":65},{"nctId":"NCT02021643","phase":"PHASE3","title":"Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-12-10","conditions":"Chronic HCV Infection","enrollment":687},{"nctId":"NCT02452814","phase":"","title":"Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-05-07","conditions":"HCV","enrollment":8},{"nctId":"NCT01439373","phase":"PHASE2","title":"Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-07","conditions":"Hepatitis C, Chronic","enrollment":16},{"nctId":"NCT03359746","phase":"PHASE4","title":"Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant","status":"UNKNOWN","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2017-12-15","conditions":"Hepatitis C","enrollment":40},{"nctId":"NCT02508090","phase":"","title":"Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-08-02","conditions":"Chronic Hepatitis C","enrollment":10},{"nctId":"NCT01659567","phase":"","title":"A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-04-06","conditions":"Hepatitis C, Chronic","enrollment":516},{"nctId":"NCT02476617","phase":"PHASE3","title":"Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-06","conditions":"Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1a","enrollment":25},{"nctId":"NCT02850289","phase":"","title":"APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-04","conditions":"Hepatitis C, Chronic","enrollment":385},{"nctId":"NCT00512278","phase":"PHASE2","title":"Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C","status":"COMPLETED","sponsor":"Nizar Zein","startDate":"2007-07","conditions":"Hepatitis C","enrollment":146},{"nctId":"NCT00803309","phase":"PHASE4","title":"Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients","status":"TERMINATED","sponsor":"HepNet Study House, German Liverfoundation","startDate":"2008-11","conditions":"Hepatitis C, Chronic","enrollment":99},{"nctId":"NCT02099604","phase":"PHASE3","title":"Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C","status":"WITHDRAWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-04","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT01962441","phase":"PHASE3","title":"SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-09-24","conditions":"Hepatitis C","enrollment":601},{"nctId":"NCT01648140","phase":"PHASE2","title":"Dose Ranging of GSK2336805 in Combination Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-08-01","conditions":"Hepatitis C, Chronic","enrollment":286},{"nctId":"NCT00317746","phase":"PHASE3","title":"Trial of Citalopram for the Prevention of Depression","status":"COMPLETED","sponsor":"Marina Klein","startDate":"2006-11","conditions":"Depression, HIV Infections, Hepatitis C","enrollment":76},{"nctId":"NCT00239733","phase":"PHASE4","title":"Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-03","conditions":"Thrombocytopenia, Hepatitis C, HIV Infections","enrollment":6},{"nctId":"NCT03090035","phase":"PHASE3","title":"Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses Chronic Hepatitis C Treatment","status":"COMPLETED","sponsor":"Sheikh Zayed Medical College","startDate":"2014-01-01","conditions":"Hepatitis C, Hepatitis C Relapse","enrollment":98},{"nctId":"NCT01482390","phase":"PHASE2","title":"A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11-30","conditions":"Hepatitis C","enrollment":80},{"nctId":"NCT02006745","phase":"PHASE3","title":"Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT)","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2014-01","conditions":"HIV","enrollment":20},{"nctId":"NCT01153919","phase":"PHASE2","title":"Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2010-06-30","conditions":"Hepatitis C Infection, Thrombocytopenia","enrollment":27},{"nctId":"NCT00493805","phase":"PHASE4","title":"Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-04","conditions":"Hepatitis C, Chronic, Insulin Resistance","enrollment":59},{"nctId":"NCT00423800","phase":"PHASE3","title":"Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12","conditions":"Hepatitis C, Chronic","enrollment":56},{"nctId":"NCT00959699","phase":"PHASE2","title":"A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"HIV Infections, Hepatitis C, HCV Infection","enrollment":99},{"nctId":"NCT00708500","phase":"PHASE3","title":"Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":404},{"nctId":"NCT00686777","phase":"PHASE4","title":"Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01","conditions":"Hepatitis C, Chronic","enrollment":75},{"nctId":"NCT00863109","phase":"","title":"Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04","conditions":"Hepatitis C, Chronic, Genotype 1, HCV-1","enrollment":133},{"nctId":"NCT00759109","phase":"PHASE3","title":"Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-03","conditions":"Carcinoma, Hepatocellular","enrollment":150},{"nctId":"NCT00255034","phase":"PHASE4","title":"Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-02","conditions":"Hepatitis C, Chronic","enrollment":146},{"nctId":"NCT00378599","phase":"PHASE3","title":"Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-05","conditions":"Liver Transplantation, Hepatitis C, Chronic, Liver Cirrhosis","enrollment":125},{"nctId":"NCT00255008","phase":"PHASE4","title":"Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Hepatitis C, Chronic","enrollment":121},{"nctId":"NCT00265395","phase":"PHASE3","title":"Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-12","conditions":"Hepatitis C, Chronic","enrollment":1428},{"nctId":"NCT00686517","phase":"PHASE3","title":"Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-12","conditions":"Hepatitis C","enrollment":130},{"nctId":"NCT00978497","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-09","conditions":"HCV Infection","enrollment":97},{"nctId":"NCT01447446","phase":"","title":"An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Hepatitis C, Chronic","enrollment":4442},{"nctId":"NCT00684268","phase":"PHASE2","title":"Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2007-10","conditions":"Hepatitis C","enrollment":70},{"nctId":"NCT01925183","phase":"PHASE4","title":"Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C","status":"COMPLETED","sponsor":"Markus Peck-Radosavljevic","startDate":"2013-08","conditions":"Hepatitis C, Chronic, HIV","enrollment":6},{"nctId":"NCT00277238","phase":"PHASE2","title":"CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-02","conditions":"Hepatitis, Chronic Active","enrollment":113},{"nctId":"NCT01980290","phase":"","title":"Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2013-05","conditions":"Hepatitis, Chronic","enrollment":50},{"nctId":"NCT00211848","phase":"PHASE2","title":"Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2000-06","conditions":"Hepatitis C","enrollment":207}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1268,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pegasys and Copegus","Pegasys and Ribavirin"],"phase":"marketed","status":"active","brandName":"Pegylated interferon and ribavirin","genericName":"Pegylated interferon and ribavirin","companyName":"Pacific Health Foundation","companyId":"pacific-health-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegylated interferon alpha activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis and replication. Used for Chronic hepatitis C virus infection (genotype-dependent).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}